Welcome to the INA-RESPOND public website.
Indonesia continues to face a dynamic and evolving infectious disease landscape that requires timely, high-quality research to inform clinical practice, public health policy, and outbreak response.
The Indonesia Research Partnership on Infectious Diseases (INA-RESPOND) is a national collaborative research network that brings together clinical and academic institutions across Indonesia, in close partnership with the Ministry of Health and international collaborators.
As part of the strengthening of Indonesia’s clinical research ecosystem, INA-RESPOND is transitioning toward a Clinical Research Unit (CRU)-based network aligned with the Indonesian Clinical Research Center (INA-CRC) framework. This approach enables a more coordinated, scalable, and responsive research platform to address priority health challenges and emerging infectious diseases.
By: Cintya Naya Danastri, Ivana Yulian, Putri Permata Sari What’s this about? World Hepatitis Day, observed every year on July 28, is one of the World Health Organization’s (WHO) nine officially designated global public health days. It serves as a global call to action to raise awareness about the burden of viral hepatitis and to
Read moreBy: INA-RESPOND CRA and CRSS Site readiness is a cornerstone of successful clinical trial execution. The journey from site activation to ongoing trial management requires careful planning, clear communication, and continuous oversight. One of the most critical steps in this process is the Site Initiation Visit (SIV), which serves as the official launch of site
Read moreBy: Caleb Leonardo Halim Hypertension, often dubbed the “silent killer,” is a global health threat that affects over one billion people worldwide. It quietly damages arteries and vital organs, significantly increasing the risk of heart disease, stroke, kidney failure, and even cognitive decline. While medications play a crucial role in managing high blood pressure, non-pharmacological
Read moreBy: Putri Permata Sari, Muhammad Ryznar Faisal Nur Luqmani, Zelfia Riyelly What’s this about? Every year, on June 14, countries worldwide commemorate World Blood Donor Day (WBDD), which was initiated by the World Health Organization (WHO) in 2004. This event aims to express gratitude to the millions of voluntary blood donors and to raise awareness
Read moreBy: Aly Diana A while ago, I discussed CRISPR (Clustered Regularly Interspaced Short Palindromic Repeats)—and honestly, the idea of editing genes still fascinates me. I remain deeply hopeful about what it could mean for the future of medicine. From time to time, I check on its progress, and I was delighted (even if a little
Read moreBy: Risky Dwi Rahayu Caffeine is one of the most widely used stimulants in the world. People usually consume it in coffee, tea, soft drinks, or chocolate, but it is also added to many sports‑nutrition products such as gels, chewing gum, energy shots, and energy drinks. Research shows that, when used correctly, caffeine can improve
Read moreBy: Rifaa’ah Rosyiidah, Adhella Menur Mental health significantly influences our well-being, productivity, relationships, and overall quality of life. As one of the leading causes of global disability, mental disorders have seen a substantial rise in prevalence, from 654.8 million cases in 1990 to 970.1 million in 2019, as per the 2019 Global Burden of Disease
Read moreTo collect standardized baseline and longitudinal data describing the course of HIV disease in antiretroviral-naive and treatment-experienced individuals to inform policy.
Implementing a Combination of Clinical Parameters (Rapid Diagnostic Tests, Biomarkers and Standard of Care Procedures) for the Etiology Diagnosis of Pneumonia in Paediatric Patients to Improve Clinical Management in Indonesia
To identify COVID-19 and other respiratory infectious disease cases from hospitalized suspected COVID-19 patients.
to compare the virological efficacy of the three regimens in the intention to treat (ITT) population. Virological efficacy is defined as the proportion of participants with plasma HIV RNA (pVL) <50 copies/mL at 48 weeks.
Among participants testing positive for SARS-CoV-2: Estimate the rate of hospitalization or death during the 28 day follow-up period. Identify risk factors for hospitalization or death.
Primary Objective: The primary endpoint of this trial in hospitalized patients is an ordinal outcome based on the patient’s clinical status on Day 7. It includes seven mutually exclusive categories capturing the range of organ dysfunction that may be associated with the progression of COVID-19, such as respiratory dysfunction and coagulation-related complications.
To characterize immunogenicity (by measurement of anti-S Ab) of available COVID-19 vaccine regimens in people who received an initial vaccine or booster regimen, in each of the countries at 2 months after completion of the initial full vaccine regimen or booster vaccine regimen.
To identify the etiology of acute febrile illness cases and evaluate clinical manifestations and outcomes.
To determine the causes of community-acquired sepsis and severe sepsis in adults and pediatrics across Southeast Asia.
To estimate the proportion of MDR TB amongst treatment naïve new treatment naïve and previously treated cases.
